Business
Medera to Present Late-Breaking Phase 1/2a Clinical Trial Results at Heart Failure 2025 Congress
BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF clinical trial investigating its adeno-associated virus-based gene therapy candidate SRD-002 in heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress taking
About this update from Keen Vision Acquisition Corporation
[{"type":"image","alt":"Medera Inc.; Keen Vision Acquisition Corporation","displaySize":"","headline":null,"caption":"Medera Inc.; Keen Vision Acquisition Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":109,"url":"https://media.zenfs.com/en/globenewswire.com/f6bc075be7aef385da5918f3e6731940"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CAhTcroBLLZxs8GBi5TjvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f6bc075be7aef385da5918f3e6731940","width":300,"height":109}},"lazy":false},{"type":"text","content":"BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing a range of next-generation therapeutics, today announced that data from its First-In-Human Phase 1/2a MUSIC-HFpEF clinical trial investigating its adeno-associated virus-based gene therapy candidate SRD-002 in heart failure with preserved ejection fraction (HFpEF) will be presented at the upcoming Heart Failure 2025 Congress taking place May 17-20, 2025, in Belgrade, Serbia.","length":544,"tagName":"p"},{"type":"text","content":"Heart failure is a global pandemic with an estimated 64.3 million cases worldwide. HFpEF accounts for nearly half of all heart failure cases but has limited disease-modifying therapeutics. The MUSIC-HFpEF trial is investigating SRD-002, a one-time gene therapy treatment delivered through a proprietary minimally invasive intracoronary infusion methodology.","length":357,"tagName":"p"},{"type":"text","content":"The late-breaking clinical trial presentation titled, "Gene therapy for heart failure with preserved ejection fraction," will be delivered by Marat Fudim, MD, MHS, Advanced Heart Failure Specialist and Associate Professor at Duke University Medical Center, on May 18, 2025, at 14:05 CEST during the "Late-Breaking Clinical Trials in Chronic Heart Failure" session.","length":384,"tagName":"p"},{"type":"text","content":""We are pleased to have our MUSIC-HFpEF trial selected for a late-breaking presentation at this prestigious international congress," said Ronald Li, Ph.D., CEO and co-founder of Medera. "Heart Failure 2025 brings together the world's leading experts in heart failure, making it an ideal forum to bring to light...